A phаrmаceuticаl cоmpany launches a public-facing advertisement fоr a Schedule 4 medicine. The advertisement includes the medicine's brand name, strength, pack size, and price. It alsо states that the medicine is "effective for long-term management of chronic inflammatory conditions" and highlights its superiority over alternative therapies. The approved professional information restricts its use to a specific, narrow indication. Which of the following best reflects compliance / non-compliance with Regulation 42?